Trial Profile
Pivotal phase II/III trial of darinaparsin in patients with peripheral T-cell lymphoma (PTCL)
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Darinaparsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Solasia Pharma
- 17 Sep 2014 New trial record
- 31 Jul 2014 This pivotal trial is expected to be initiated in Asia in early 2015, according to a ZIOPHARM Oncology media release.